PERSPECTIVE THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2026-06-30 was -$0.22.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was -$0.35.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$0.30.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2025-03-31 was -$0.25.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$1.41.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$1.22.
- PERSPECTIVE THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$1.40.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.22 10-Q · filed 2026-08-10 | -$0.47 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | -$1.41 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$0.35 10-Q · filed 2025-11-10 | -$0.90 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$0.30 10-Q · filed 2026-08-10 | -$0.55 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$0.25 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | -$1.22 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | -$0.21 10-Q · filed 2025-11-10 | -$0.61 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$0.17 10-Q · filed 2025-08-13 | -$0.40 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$0.24 10-Q · filed 2025-05-12 | -$0.02 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | -$1.40 10-K/A · filed 2025-03-28 | ||||
| 2023-09-30 | -$0.34 10-Q · filed 2024-11-12 | -$0.68 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$0.34 10-Q · filed 2024-08-13 | -$0.33 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | $0.01 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |